Takuna (Cecropia strigosa): A Comprehensive Reference
1. Identity
Botanical Name and Taxonomy
Takuna is an extract from the bark of Cecropia strigosa, which belongs to the Urticaceae family. It is also known botanically as Cecropia bicolor, Cecropia multiflora, Cecropia rugosa, Ambaiba bicolor, and Ambaiba strigosa, though Latin binomials other than Cecropia strigosa are considered obsolete. The genus Cecropia itself is large and well-documented: Cecropia is a genus of fast-growing trees in the nettle family (Urticaceae), with around 63 recognized species spread across Central and South America.
Common Names
Common names for Cecropia strigosa include Takuna, Snakewood tree, Trumpet tree, Yagrumo hembra, Cecropias, and Pumpwood. Embauba is the common name used in Brazil; it comes from the Tupi word ambaiba, which means hollow trunk. In Peru, the tree is commonly known as Tacona blanco.
Natural Source and Geographic Range
C. strigosa's natural habitat ranges from the Amazonian region to the Andes. More broadly, the Cecropia genus is found across key countries such as Guatemala, Nicaragua, Venezuela, Colombia, Ecuador, Peru, Brazil, and Argentina. Their umbrella-like crowns catch sunlight that floods forest gaps, making Cecropia one of the most distinctive and important pioneer species in the Amazon. Ecologically, Cecropia plays a foundational role in forest regeneration, thriving where other trees struggle — on landslides, riverbanks, and abandoned clearings.
These trees usually live about 30 years and grow to less than 18 metres (60 feet), producing a very soft wood. Trees are either male or female, with the female producing nearly one million seeds every time it fruits.
Botanical Features
The tree is easily recognized by its thin, white-ringed trunk and umbrella-like arrangement of large leaves at the branch tips. A notable ecological feature is the Cecropia's interaction with Azteca ants, a classic case of defense mutualism in the tropics; the tree provides the ants with a nest consisting of multiple chambers within the stems as the ants burrow through the soft internal tissue.
Common Preparations and Dosage Forms
Commercially, Takuna is most commonly produced as a liquid bark extract (tincture). Ingredients in commercial preparations typically include pure cane alcohol, osmotic water, and Cecropia (Cecropia strigosa) bark from Peru. Each standard tincture is typically a 1:3 preparation using 55% alcohol, provided in glass bottles with a calibrated dropper for easy dispensing. Most of the plant material is grown in Peru, where it is ecologically wildcrafted.
Each 1.5 ml (30 drops) of a typical commercial product contains a Cecropia alcohol-water extract equivalent to 500 mg of Cecropia bark.
2. Traditional and Historical Use
Ethnobotanical Background
Cecropia species have been used in traditional medicine for centuries, across Latin American cultures where these plants have been revered for their healing properties. These practices leverage different parts of the plant, including leaves, bark, and roots, to treat respiratory disorders such as asthma and bronchitis, hypertension, diabetes, kidney disorders, cardiovascular complications, and inflammatory conditions.
Several Cecropia species are traditionally used in Latin America for the treatment of a variety of diseases including diabetes, arterial hypertension, asthma, bronchitis, anxiety, and inflammation.
Amazonian Indigenous Use
Indian tribes in the Amazon use embauba for its anti-inflammatory properties — typically for rheumatic, kidney, and lung inflammations. The leaf is made into a tea and used widely for asthma and other upper respiratory complaints, as well as for diabetes. The traditional ethnobotanical use of C. strigosa specifically is for gastrointestinal support.
Mexican and Central American Traditions
Commonly called "Guarumbo," "Chancarro," and "Hormiguillo," Cecropia obtusifolia is widely used by Mexican traditional healers for the treatment of type 2 diabetes. Previous ethnobotanical studies have reported that a mean of 12–15 g of the dry leaves boiled in 1 litre of water must be consumed several times per day as agua de uso (water which is normally consumed throughout the day).
The same genus is also utilized in traditional medicine in Panama to treat cardiovascular diseases, and in Mexico for conditions like cough, asthma, bronchitis, fever, hepatic and kidney diseases, rheumatism, and inflammation, as well as for its diuretic effect.
Brazilian Traditional Use
The Cecropia genus consists of about 60 species distributed throughout Latin America, mostly in Brazil, where these species are widely used in traditional medicine to treat cough, asthma, bronchitis, high blood pressure, inflammation, heart disease, and as a diuretic. Popularly known in Brazil as embaúba, umbaúba, imbaúba, and embaúva, it has been used in folk medicine as a diuretic and for the treatment of asthma, cough, hypertension, diabetes, and inflammation.
Specific Preparation Methods Reported in Traditional Contexts
- Indigenous Amazonian tribes use leaves made into a tea for asthma, respiratory complaints, and diabetes, and employ the plant topically for rheumatic, kidney, and lung inflammations.
- Mexican healers traditionally prepare the dried leaves by boiling 12–15 g in 1 litre of water, consumed multiple times daily.
- Bark preparations, such as tinctures and decoctions, are the basis for the most commercially prevalent modern supplement form, Takuna.
3. Key Constituents and Active Compounds
Polyphenols: Phenolic Acids and Flavonoid C-Glycosides
Research across multiple Cecropia species has identified a consistent suite of major bioactive compounds. Chlorogenic acid and flavone C-glycosides (such as orientin, isoorientin, vitexin, and isovitexin) have been consistently reported as the main compounds in C. obtusifolia, C. peltata, C. glaziovii, C. pachystachya, and C. hololeuca.
Embauba contains 47 different polyphenols. The polyphenols provided in the highest amounts include chlorogenic acid, isoorientin, orientin, and vitexin. All species of Cecropia trees contain these four polyphenols, which are now used as chemical markers to identify the trees.
Additionally, O-glycosyl flavonols (quercetin, rutin, and isoquercitrin), flavan-3-ols (catechin and epicatechin), and condensed tannins (procyanidin B2, B3, B5, and C1) have been described in certain species.
Terpenoids and Steroids
Chemical markers identified in Cecropia species also include steroids (β-sitosterol) and triterpenoids (α-amyrin, pomolic, tormentic, and ursolic acids). Concerning chemical composition, C-glycosylflavonoids and proanthocyanidins have been described as the main constituents of C. glaziovii, C. hololeuca, and C. pachystachya, while terpenoids and steroids have been reported in several species.
Established Mechanisms of Action
Hypoglycemic activity: The antidiabetic properties of Cecropia obtusifolia are attributed to chlorogenic acid (CGA) and isoorientin (ISO) phenolic compounds; both compounds possess hypoglycemic, hypolipidemic, and antioxidant properties. The role of chlorogenic acid and isoorientin in the hypoglycaemic effect of C. obtusifolia and C. peltata has been well established. Research suggests the mechanism of action of aqueous extracts of C. obtusifolia is not brought about by stimulating insulin secretion.
Anti-inflammatory activity: The anti-hypertensive and anti-inflammatory activities of C. glaziovii and C. pachystachya have been correlated to the presence of flavonoids, catechins, proanthocyanidins, terpenic, and steroidal compounds. The n-hexane extract of C. pachystachya exhibited a significant anti-inflammatory effect and sitosterol (β-sitosterol) was the only isolated compound with a highly significant anti-inflammatory activity.
Cardiovascular mechanisms (ursolic and pomolic acids): The inhibition of NF-κB-mediated inflammatory pathways and the increased scavenging of reactive oxygen species (ROS) are among the most beneficial effects of ursolic acid. In mice and rats, administration of ursolic acid appears to slow down the development of cardiovascular diseases, especially atherosclerosis and cardiac fibrosis. Upregulation of endothelial-type nitric oxide synthase (eNOS) may suggest its vasorelaxant property.
11β-HSD1 inhibition (pentacyclic triterpenes): Several lines of evidence indicate that pentacyclic triterpenes found in Cecropia species inhibit the 11β-hydroxysteroid dehydrogenase type 1 enzyme, which highlights the potential use of this type of natural product as a phytotherapeutic or botanical dietary supplement. These results partially explain the effectiveness of Cecropia as a phytotherapeutic supplement and strengthen the ethnopharmacological use of plants from the genus for treating metabolic disorders.
Quorum sensing inhibition: C-glycosyl flavonoids (orientin, isoorientin, vitexin, and isovitexin), rutin, and chlorogenic acid — all isolated from leaf extracts of Cecropia — have been reported as quorum sensing (QS) inhibitors, which may contribute to antimicrobial properties.
4. Scientific Evidence by Area of Use
Note: The overwhelming majority of pharmacological research on the genus Cecropia concerns species other than C. strigosa (particularly C. obtusifolia, C. pachystachya, C. peltata, and C. glaziovii). Specific published clinical or preclinical studies on C. strigosa as the active ingredient in "Takuna" supplements could not be verified in peer-reviewed databases at the time of writing. The evidence below pertains to closely related Cecropia species, which share the genus's characteristic phytochemical profile. Evidence strength is characterized explicitly for each area.
4.1 Blood Glucose Regulation and Type 2 Diabetes
This is the most evidence-rich area for the genus. One recurring use of the Cecropia genus across different countries in South America is its application in lowering blood sugar levels and preventing type 2 diabetes.
Human / Clinical Evidence: A double-blind clinical trial included 43 outpatients with type 2 diabetes. Based on European NIDDM criteria, only patients with poor response to conventional treatment were selected. All patients maintained their medical treatment and also received an infusion of the dry leaves of the plant for 21 days. In a double-blind manner, 22 patients were treated with C. obtusifolia and 21 with M. vulgare. Fasting blood glucose values were reduced by 15.25% in patients treated with C. obtusifolia, while cholesterol and triglycerides were decreased by 14.62% and 42.0%, respectively (ANOVA p<0.02).
Two clinical trials showed beneficial effects of extracts of this species. In an additional trial, HbA1c was significantly reduced after 6 weeks of treatment. No significant changes in cholesterol, triglycerides, ALT, AST, ALKP, or insulin were detected. No collateral effects were observed. After suspending administration and a follow-up of 34 weeks, glucose and HbA1c levels increased, reaching levels higher than basal ones.
As one limitation, as the patients also received glibenclamide at varying doses in some trials, the effects cannot be attributed to C. obtusifolia alone. An additional non-controlled clinical trial (12 type 2 diabetics, aqueous extract of 13.5 g dry leaves per day for 32 days orally) showed significant reductions in plasma glucose and glycosylated hemoglobin levels.
Animal Evidence: In diabetic rats, a methanolic extract of C. pachystachya caused a significant hypoglycemic effect with a blood glucose reduction of 68% after 12 hours. Chlorogenic acid and C-glycosylated flavonoids may explain these activities.
Evidence Strength: There are at least two small human clinical trials showing statistically significant effects on fasting glucose, though both are of short duration, used confounded drug regimens, and included small sample sizes. Animal (rodent) data corroborate the effect across multiple species. Evidence is preliminary to moderate, with no large, placebo-controlled randomized trial published as of this writing.
4.2 Anti-Inflammatory Effects
In Vitro and Animal Evidence: The methanol leaf extract of C. pachystachya was tested for anti-inflammatory effects using the croton oil-induced ear edema test. When used orally, the anti-inflammatory effect at 300 mg/kg was similar to that of indomethacin with 53% inhibition of the ear edema. Results on topical treatment were similar to dexamethasone, with 83% inhibition of the edema.
A C. pachystachya methanolic extract exhibited significant anti-inflammatory effect in acute models, in some cases comparable to reference drugs. Histopathological analysis showed a moderate chronic skin anti-inflammatory effect with decrease in vasodilation, edema, cell infiltration, and epidermal hyperproliferation.
Evidence Strength: Preclinical (rodent and in vitro) evidence is consistent across multiple species. No human clinical trials specifically evaluating anti-inflammatory outcomes for Cecropia extracts were identified in the literature.
4.3 Antihypertensive and Cardiovascular Effects
Extracts prepared from leaves of C. obtusifolia have shown antihypertensive and muscle relaxant properties in preclinical settings. Among the pharmacological activities of C. pachystachya reported in the literature are sedative, cardiotonic, hypoglycemic, anti-inflammatory, antihypertensive, and antidepressant properties.
The leaves of C. pachystachya exhibit bronchodilator and cardiovascular activity, and are described as cardiotonic and sedative.
Evidence Strength: Evidence is limited to animal and in vitro studies. No controlled human clinical trials specifically examining antihypertensive outcomes for Cecropia preparations have been identified.
4.4 Antioxidant Effects
A C. pachystachya methanolic extract showed strong in vitro antioxidant activity in multiple assay models. Studies on Cecropia species suggested the relationship between the major compounds of the leaf extracts — chlorogenic acid and glycosyl flavonoids (orientin, isoorientin, vitexin, and rutin) — and anti-diabetic, anti-inflammatory, and anti-hypertensive activities, with antioxidant mechanisms proposed as a shared underlying pathway.
Evidence Strength: In vitro antioxidant evidence is well established and consistent. In vivo and human antioxidant efficacy data are not established.
4.5 Antimicrobial (Antibacterial, Antifungal, and Antiviral) Effects
Species of the genus Cecropia, such as C. pachystachya, C. glaziovii, and C. obtusifolia, have been the subject of several phytochemical studies, and the main isolated compounds — orientin, isoorientin, isovitexin, and vitexin — were characterized as responsible for antimicrobial activity among other properties.
Extracts of C. peltata showed cytotoxic, antibacterial, and antifungal activities.
Commercial Takuna products are prominently marketed for antiviral and microbial defense properties. However, the primary published scientific literature on antimicrobial activity focuses predominantly on in vitro (cell culture or disk diffusion) assays against a limited panel of test organisms. In general, the reports are of pre-clinical investigations, and there have only been two clinical studies across the genus — both of which concerned blood glucose, not antimicrobial endpoints.
Evidence Strength: In vitro antimicrobial activity has been documented for several Cecropia species. No peer-reviewed human clinical trials specifically examining antiviral or antibacterial outcomes for C. strigosa or any other Cecropia species have been identified in the literature. Claims of efficacy against specific viruses (influenza, cytomegalovirus, Epstein-Barr virus, etc.) that appear in commercial product descriptions are not supported by published clinical evidence.
4.6 Respiratory System (Asthma and Bronchitis)
Multiple Cecropia species are widely used as antitussives and expectorants in traditional medicine and for the treatment of cough and asthma. C. pachystachya is used by indigenous populations in the treatment of bronchitis, asthma, high blood pressure, fever, and as a diuretic.
Evidence Strength: Traditional use for respiratory conditions is well documented ethnobotanically. Bronchodilator activity has been noted in animal studies. No clinical trials in humans were identified.
4.7 Central Nervous System and Mood Effects
Pharmacological activities reported for C. pachystachya in the literature include sedative and antidepressant properties.
Evidence Strength: These findings are based on preclinical animal models only. No human studies were identified.
5. Body Systems and Health Areas Associated with Cecropia / Takuna
- Metabolic / Endocrine System: Blood glucose regulation, insulin sensitivity, lipid-lowering effects — the use of C. obtusifolia in managing diabetes and cardiovascular diseases is well-documented, particularly in regions such as Mexico, Guatemala, and the Amazon Basin.
- Immune System: Antimicrobial activity (in vitro), quorum sensing inhibition, traditionally used for infections and fever.
- Cardiovascular System: Antihypertensive activity reported in preclinical models; cardiotonic, diuretic, and antioxidant effects described for multiple species.
- Respiratory System: Antitussive, expectorant, bronchodilatory effects documented in traditional use and some preclinical work.
- Gastrointestinal System: The traditional ethnobotanical use of C. strigosa specifically includes gastrointestinal support.
- Musculoskeletal / Anti-Inflammatory: Traditional use for rheumatic inflammations; preclinical anti-inflammatory data.
- Central Nervous System: Sedative and antidepressant effects described in preclinical models for related species.
6. Dosage Forms and Reported Dosages
Commercial Tincture (Bark Extract)
Suggested adult use (age 16+) in one commercial product is 15–30 drops, 2 times daily in 120 ml (4 oz.) of water. The manufacturer recommends starting with a lower dose of 1 drop and titrating up to 30 drops unless otherwise advised; the maximum is 60 drops per day.
Another commercial direction states: put 15 to 30 drops in 4 oz (120 mL) of water and wait one minute before drinking. Some product labels recommend 2–4 times per day, or for maximum support every 15 minutes.
Traditional and Clinical Leaf Preparations
Traditional ethnobotanical use in Mexico involves a mean of 12–15 g of dry leaves boiled in 1 litre of water, consumed several times per day.
A non-controlled clinical trial used an aqueous extract equivalent to 13.5 g of dry leaves per day for 32 days.
In a rodent study using a C. peltata ethanolic extract, male Wistar rats were co-administered with 10 mg/kg/day of CP extract for 90 days.
No standardized, clinically validated dosage has been established for any Cecropia species or preparation in a formal pharmacopeial or regulatory monograph.
7. Safety Considerations
Genotoxicity and Cytotoxicity Studies
Toxicological studies on C. obtusifolia have provided evidence of its safety in both in vivo and in vitro settings. A study using the Drosophila wing somatic mutation and recombination test (SMART) tested extract concentrations ranging from 0.82 to 13.32 mg/ml and found no genotoxic effects. Furthermore, the human micronucleus assay, conducted on lymphocytes from six type 2 diabetic patients who consumed 13.5 g/day of the extract for 32–85 days, reported no significant increase in cytotoxicity or genotoxicity. These findings indicate that C. obtusifolia does not pose a genotoxic risk, and its use in traditional medicine, particularly for diabetes management, appears to be safe.
In vivo, Wistar rats administered a single dose of 2000 mg/kg of the crude aqueous extract of C. pachystachya showed a reduction in hemoglobin levels after 14 days, although no significant toxicity was observed after 28 days of treatment. While these results suggest that C. pachystachya has some potential cytotoxic and genotoxic effects in vitro, no severe toxicity was detected in animal studies under tested conditions. Further research is needed to clarify the long-term safety of C. pachystachya extracts and to establish safe dosage ranges for its medicinal use.
For C. glaziovii, at concentrations tested, no acute toxicity, clastogenic, or aneugenic activity was observed, suggesting the extract does not interfere in cell division.
Clinical Safety Reports
In the human clinical trial of C. obtusifolia for type 2 diabetes, no collateral effects were observed. The aqueous extracts of C. obtusifolia were reported to have a significant hypoglycemic effect with no adverse effects noted.
Product Quality and Adulteration Concerns
Despite the fact that herbal medicines are popularly consumed and are widely recognized as safe, several adverse reactions have been associated with their use. Variable composition, the presence of toxic contaminants, pesticides, microbial contaminants, and adulteration with other plant species or synthetic drugs can affect their quality, efficacy, and safety. A number of commercial products based on medicinal plants have been introduced into the market with very little information about their chemical constituents, and plants of the genus Cecropia are a representative example of this situation.
Potential Interactions
Based on the documented pharmacological properties of the genus, the following interactions are plausible and warrant attention:
- Antidiabetic drugs: Given established hypoglycemic effects, concurrent use of Cecropia preparations with antidiabetic medications (e.g., metformin, sulfonylureas, insulin) could potentially result in additive blood glucose-lowering effects. The published clinical trial noted that participants were also receiving glibenclamide.
- Antihypertensive drugs: Preclinical antihypertensive and diuretic effects suggest a theoretical potential for additive hypotensive effects when combined with antihypertensive agents.
- High alcohol content in tincture preparations: Commercial tincture formulations contain approximately 55 vol.% alcohol, which should be noted for individuals with alcohol sensitivity, liver conditions, or those taking medications incompatible with alcohol.
Absence of Formal Monographs
At present, a number of commercial products based on these plants have been introduced into the market with very little information on methods for guaranteeing their quality and safety. It is necessary to establish comprehensive standards for guaranteeing quality, safety, and efficacy of herbal drugs. The selection of adequate chemical markers for quality control purposes requires a good knowledge about the chemical composition of medicinal plants and their associated biological properties. No official monograph from the WHO, European Medicines Agency (EMA), ESCOP, or United States Pharmacopeia (USP) specific to Cecropia strigosa has been published as of the time of writing.
8. Summary of Evidence Appraisal
The supplement "Takuna" is a bark extract of Cecropia strigosa, a species within a well-studied neotropical genus. The genus Cecropia has a robust body of phytochemical research identifying consistent bioactive compounds (chlorogenic acid, isoorientin, orientin, vitexin, ursolic acid, pomolic acid, β-sitosterol, and procyanidins) across multiple species. For the most researched indication — blood glucose regulation in type 2 diabetes — there are two small human clinical trials involving C. obtusifolia showing statistically significant effects, supported by consistent animal and in vitro data. For all other indications (anti-inflammatory, antiviral, antihypertensive, bronchodilatory), evidence remains at the preclinical stage. In general, the reports for the genus are of pre-clinical investigations, with only two clinical studies having been conducted across the entire genus. Species-specific data for C. strigosa itself, as "Takuna," are very limited in the peer-reviewed literature, and extrapolation from better-studied congeners requires caution.
References
Go back